Clinical trials: Oligometastatic Disease, active
Oligometastasis, Oligometastatic Disease
Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)
This study is for participants whose cancer is oligometastatic, meaning it has spread to up to five spots in their body and their doctor recommends that they have stereotactic body radiation therapy (SBRT) to treat these cancer…
- Trial name
- NCT07079098
- Testing
- Simulation-free workflow, SBRT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
Oligometastatic Disease, Oligoprogression
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs.
- Conditions
- Oligometastatic Disease, Oligoprogression, Toxicity Due to Radiotherapy, Quality of Life
- Trial name
- NCT05784428
- Testing
- Single fraction SABR, Multiple fraction SABR, QoL reporting alone
- Where
- 14 sites in Canada, Ireland
- Volunteers
- 598 people
- Sponsor
- Robert Olson
Breast Cancer Stage IV, Oligometastatic Disease
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy…
- Trial name
- TAORMINA (NCT05377047)
- Testing
- SABR
- Where
- 19 sites in Ireland, Israel and 4 more
- Volunteers
- 345 people
- Sponsor
- Vastra Gotaland Region
Nasopharyngeal Carcinoma, Neoplasm Metastasis
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic…
- Conditions
- Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
- Trial name
- NCT07824856
- Testing
- CT-guided percutaneous local ablation, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Oligometastatic Disease, Prostatic Cancer, Castration-Resistant
Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer
The purpose of this randomized trial is to investigate the efficacy and toxicity of percutaneous high-dose radiotherapy in patients with oligometastases of hormone refractory prostate cancer.
- Trial name
- OLI-CR-P (NCT04141709)
- Testing
- local ablative radiotherapy
- Where
- 4 sites in Germany
- Volunteers
- 66 people
- Sponsor
- Technische Universität Dresden
Oligometastatic Disease
Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography
The prospective single-arm pilot study, ATHERO-RT: Real-Time Atherosclerosis Activity after Thoracic Radiotherapy using Sodium Fluoride Positron Emission Tomography, will aim to: 1.
- Trial name
- NCT06373497
- Testing
- 18-F-NaF Cardiac PET/MRI and, CT Angiogram
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Katelyn Atkins
Prostate Cancer, Castrate Sensitive Prostate Cancer
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer.
- Conditions
- Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
- Trial name
- NCT04748042
- Testing
- Abiraterone, Prednisone, External Beam Radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer Metastatic Disease, Oligometastatic Prostate Cancer (OMPC)
HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS)
The investigators propose redefining this concept by focusing on volume rather than the number of metastases. To achieve this, the investigators aim to determine the Maximum Tolerated Volume (MTV) of metastatic lesions treatable…
- Trial name
- HIMARS (NCT06978296)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer, Oligometastatic Disease
TERPS Trial for de Novo Oligometastic Prostate Cancer
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
- Trial name
- NCT05223803
- Testing
- Prostate radiation (XRT), Systemic Therapy, Stereotactic ablative radiation therapy (SABR)
- Where
- 10 sites in United States
- Volunteers
- 122 people
- Sponsor
- University of Maryland, Baltimore
Peritoneal Carcinomatosis, Oligometastatic Disease
MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).
This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors.
- Conditions
- Peritoneal Carcinomatosis, Oligometastatic Disease, Peritoneal Metastases
- Trial name
- MARACAS (NCT07593261)
- Testing
- MRI-guided stereotactic body radiotherapy
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colorectal Cancer, Oligometastatic Disease
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic…
- Trial name
- RESOLUTE (NCT05862051)
- Testing
- Local Ablative Therapy, Standard first-line systemic treatment
- Where
- 9 sites in Australia
- Volunteers
- 6 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Prostate Cancer, Oligometastatic Disease
High-Risk Metachronous Oligometastatic Prostate Cancer Trial
The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of…
- Trial name
- KNIGHTS (NCT06212583)
- Testing
- niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Maryland, Baltimore
Ovarian Cancer, Oligometastatic Disease
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with…
- Conditions
- Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
- Trial name
- ANALLISA (NCT06180356)
- Testing
- Niraparib oral tablets
- Where
- 14 sites in Spain
- Volunteers
- 30 people
- Sponsor
- MedSIR
Oligometastatic Disease
125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer
Most patients with metastatic cancer eventually develop resistance to systemic therapy. A subset of patients experience oligoprogression, characterized by progression at a limited number of lesions while other disease sites…
- Trial name
- NCT07333651
- Testing
- Standard-of-Care Systemic Therapy, 125I Seed Implantation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
Oligoprogression, Oligometastatic Disease
Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers
STOP-2 is a phase III multi-institutional double-blind randomized trial. 194 participants will be enrolled in this trial. Participants will be randomized in a 1:1 ratio between the Control Arm vs. the Experimental Arm.
- Conditions
- Oligoprogression, Oligometastatic Disease, OligoProgressive Metastatic Disease
- Trial name
- NCT06918951
- Testing
- Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy
- Where
- Canada
- Volunteers
- 194 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer, Radiotherapy Side Effect
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
- Trial name
- SMART-P01/02 (NCT05183074)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oligometastatic Disease, Solid Tumor, Adult
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
The goal of this clinical trial is to assess safety of pan-metastases directed SBRT combined with ATRA and the lympho-protective efficacy of ATRA upon radiation-induced lymphopenia.
- Trial name
- LySATRA (NCT06439888)
- Testing
- all-trans retinoic acid, Stereotactic Body Radiation Therapy
- Where
- 2 sites in France
- Volunteers
- 58 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Oligometastatic Disease, Non-small Cell Lung Cancer
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
- Conditions
- Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
- Trial name
- TARGET-01 (NCT05277844)
- Testing
- Local Consolidative Radiation Therapy, TKI
- Where
- India
- Volunteers
- 106 people
- Sponsor
- Tata Memorial Hospital
Oligometastatic Disease, Metastatic Non Small Cell Lung Cancer
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial
- Trial name
- TARGET-02 (NCT05278052)
- Testing
- Local consolidative radiation therapy, Standard maintenance therapy as decided by the treating medical oncologist
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Tata Memorial Hospital
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC